Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet-Reference-Cited by-同舟云学术

Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet

Published:2011-05 Issue:5 Volume:60 Page:617-628
ISSN:0026-0495
Container-title:Metabolism
language:en
Short-container-title:Metabolism

Author:

Muraoka Tomonori,Aoki Kazutaka,Iwasaki Tomoyuki,Shinoda Kazuaki,Nakamura Akinobu,Aburatani Hiroyuki,Mori Shuuichi,Tokuyama Kumpei,Kubota Naoto,Kadowaki Takashi,Terauchi Yasuo

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference38 articles.

1. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption;Altmann;Science,2004

2. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia;Davies;J Biol Chem,2005

3. Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters;Valasek;Am J Physiol Gastrointest Liver Physiol,2008

4. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome;Deushi;FEBS Lett,2007

5. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1−/− mice;Labonté;Am J Physiol Gastrointest Liver Physiol,2008

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sterol Regulatory Element Binding Protein 1: A Mediator for High-Fat Diet–Induced Hepatic Gluconeogenesis and Glucose Intolerance in Fish;The Journal of Nutrition;2024-05

2. MiR-203 is an anti-obese microRNA by targeting apical sodium-dependent bile acid transporter;iScience;2022-08

3. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study);BMC Medicine;2022-03-21

4. Is there a role of lipid-lowering therapies in the management of fatty liver disease?;World Journal of Hepatology;2022-01-27

5. Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model;Gastroenterology Report;2022-01-01